Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of March 15, 2020.